Publicaciones en las que colabora con Pilar Garrido López (25)

2024

  1. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  2. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

2023

  1. Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2022), 10.1007/s12094-022-03046-9)

    Clinical and Translational Oncology

  2. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 25, Núm. 5, pp. 1252-1267

  3. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 56, Núm. 2, pp. 97-112

2021

  1. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

    Clinical and Translational Oncology, Vol. 23, Núm. 8, pp. 1529-1541

  2. Multidisciplinary consensus on optimizing the detection of NTRK gene alterations in tumours

    Revista Espanola de Patologia, Vol. 54, Núm. 4, pp. 250-262

  3. Screening for ROS1 fusions in patients with advanced non-small cell lung carcinomas using the VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody

    Expert Review of Molecular Diagnostics, Vol. 21, Núm. 5, pp. 437-444

  4. Tumor mutational burden assessment in non-small-cell lung cancer samples: Results from the TMB 2 harmonization project comparing three NGS panels

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5

2020

  1. Correction to: Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2020), 22, 6, (823-834), 10.1007/s12094-019-02211-x)

    Clinical and Translational Oncology

  2. Liquid biopsy in oncology: A consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 53, Núm. 4, pp. 234-245

  3. Liquid biopsy in oncology: a consensus statement of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 22, Núm. 6, pp. 823-834

  4. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 167-181

  5. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 22, Núm. 7, pp. 989-1003

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2018

  1. Aligning digital CD8 + scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma

    Histopathology, Vol. 72, Núm. 2, pp. 270-284

2017

  1. A consensus statement on the gender perspective in lung cancer

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535

  2. Treating KRAS -mutant NSCLC: Latest evidence and clinical consequences

    Therapeutic Advances in Medical Oncology, Vol. 9, Núm. 9, pp. 589-597

2015

  1. Actualización de las recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón avanzado de célula no pequeña. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Españ

    Revista Espanola de Patologia

2014

  1. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9